Please login to the form below

Not currently logged in
Email:
Password:

J&J aims to buy Crucell

Johnson & Johnson has announced that it is in advanced negotiations to buy the Dutch biotech firm Crucell for €1.75bn in cash

Johnson & Johnson (J&J) has announced that it is in advanced negotiations to buy the Dutch biotech firm Crucell for €1.75bn in cash.

The move is intended to bolster J&J's presence in the vaccines market. Crucell develops and produces vaccines, proteins and antibodies aimed at infectious diseases, with a focus on developing countries. The company's core product portfolio includes the fully-liquid pentavalent vaccine Quinvaxem, which protects against five childhood diseases and has sold over 130 million doses in the developing world since its 2006 launch.

J&J said Netherlands-based Crucell would be the vaccines center of the J&J pharmaceutical group but would be encouraged to "retain its entrepreneurial culture."

J&J already owns 17.9 per cent of the outstanding shares of Crucell through an affiliate. The company bought that stake for €301.8m last year as part of a partnership focused on vaccines for influenza. The initial focus of the partnership, which was forged with J&J's Ortho-McNeil-Janssen Pharmaceuticals, has been a universal monoclonal antibody product for the treatment and prevention of flu.

The US company is now proposing to acquire all of Crucell's remaining equity for €24.75 per share.

J&J said that it expects to leave Crucell's senior management team in place and is not planning significant layoffs. Crucell is headed up by Ronald Brus, president and CEO, who was formerly chief operating officer and, before that, chief business officer of the company. He has also been a product planning physician at Forest Laboratories in New York and medical director for Zambon.

J&J and Crucell stressed that there is not yet a definitive agreement for a merger and that terms are still being negotiated.

20th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....